Sjögren’s Syndrome (SS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Sjögren’s Syndrome (SS) Market Outlook

Thelansis’s “Sjögren’s Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sjögren’s Syndrome (SS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sjögren’s Syndrome (SS) Overview

Sjögren syndrome (SS) is a gradually progressing autoimmune disorder with various organ-specific and systemic symptoms. In SS patients, B-cell activation is consistently observed, leading to the infiltration of B and T cells into target organs, resulting in damage. The typical SS patient, most commonly perimenopausal women, experiences reduced lacrimal and salivary gland function symptoms. Common manifestations include dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca), and enlargement of the parotid glands. The oral dryness experienced by SS patients can significantly impact their quality of life, interfering with basic daily activities like eating, speaking, and sleeping. The reduction in salivary volume also reduces saliva’s natural antibacterial properties, increasing the risk of infections, tooth decay, and periodontal disease. SS patients often complain of ocular discomfort, including itching, grittiness, soreness, and dryness, despite the outward appearance of normal eyes. The reduced tear secretion can lead to chronic irritation and damage to the corneal and bulbar conjunctival epithelium (keratoconjunctivitis sicca). Salivary gland swelling, initially unilateral but often becoming bilateral, can be either chronic or episodic. Sjögren syndrome can occur independently as primary SS or in conjunction with systemic autoimmune rheumatic diseases, referred to as secondary SS. Because SS symptoms may not manifest simultaneously, medical professionals, including physicians and dentists, may treat individual symptoms without recognizing the underlying systemic disease. The differential diagnosis of SS involves considering conditions and medications that can cause symptoms such as keratoconjunctivitis sicca, xerostomia, and parotid gland enlargement. Two FDA-approved drugs, Salagen (pilocarpine) and Evoxac (cevimeline), can increase saliva production and treat dry mouth in SS. The prevalence of SS varies significantly across different reports, with changes of up to tenfold noted between countries and within the same country.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Sjögren’s Syndrome (SS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034